Hypogonadism in men with prolactinoma

Hypogonadism is one of the most consequential manifestations of prolactinoma in men, yet its course is often reduced to a single testosterone result. Prolactin excess can reversibly suppress hypothalamic-pituitary-gonadal signalling, whereas large tumours may damage gonadotroph function and other pituitary axes. These mechanisms create a dynamic phenotype that includes androgen-deficiency symptoms, impaired spermatogenesis, anaemia, adverse body composition, skeletal fragility and sexual dysfunction. Dopamine agonists are the usual first causal treatment, and transsphenoidal surgery is appropriate in selected patients; neither biochemical control nor tumour shrinkage proves gonadal or sexual recovery. Contemporary cohorts indicate that testosterone recovery occurs mainly during the first year but may continue through 24 months, and is more likely with smaller tumours, higher baseline or six-month testosterone, earlier prolactin normalisation and preserved pituitary function. Men with persistent symptomatic hypogonadism require a fertility-sensitive decision: continued observation when recovery remains plausible, consideration of testosterone replacement when fertility is not sought, or specialist gonadotrophin treatment when fertility is desired; clomiphene is an off-label option supported only by small uncontrolled studies. Sexual desire and erectile function should be measured separately because both may remain impaired despite eugonadism and require additional cardiometabolic, medication and psychosexual assessment. This Review integrates endocrine, reproductive and sexual outcomes into a time-resolved framework. The central principle is that prolactin control, endogenous gonadal recovery, fertility and sexual recovery are related but non-equivalent treatment goals.

Authors

Institutions

Publication Details

Journal
European Journal of Endocrinology
Published
2026-11-18
DOI
https://doi.org/10.1093/ejendo/lvag220
Primary Topic
Pituitary Gland Disorders and Treatments
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Hypogonadism in men with prolactinoma

Alberto Malucelli, Marek Broul, Michal Vostrý, Lucie Radovnická et al.
4 links
European Journal of Endocrinology
Pituitary Gland Disorders and Treatments
article

Hypogonadism in men with prolactinoma

Alberto Malucelli, Marek Broul, Michal Vostrý, Lucie Radovnická, Aneta Hujová
article en

Abstract

Hypogonadism is one of the most consequential manifestations of prolactinoma in men, yet its course is often reduced to a single testosterone result. Prolactin excess can reversibly suppress hypothalamic-pituitary-gonadal signalling, whereas large tumours may damage gonadotroph function and other pituitary axes. These mechanisms create a dynamic phenotype that includes androgen-deficiency symptoms, impaired spermatogenesis, anaemia, adverse body composition, skeletal fragility and sexual dysfunction. Dopamine agonists are the usual first causal treatment, and transsphenoidal surgery is appropriate in selected patients; neither biochemical control nor tumour shrinkage proves gonadal or sexual recovery. Contemporary cohorts indicate that testosterone recovery occurs mainly during the first year but may continue through 24 months, and is more likely with smaller tumours, higher baseline or six-month testosterone, earlier prolactin normalisation and preserved pituitary function. Men with persistent symptomatic hypogonadism require a fertility-sensitive decision: continued observation when recovery remains plausible, consideration of testosterone replacement when fertility is not sought, or specialist gonadotrophin treatment when fertility is desired; clomiphene is an off-label option supported only by small uncontrolled studies. Sexual desire and erectile function should be measured separately because both may remain impaired despite eugonadism and require additional cardiometabolic, medication and psychosexual assessment. This Review integrates endocrine, reproductive and sexual outcomes into a time-resolved framework. The central principle is that prolactin control, endogenous gonadal recovery, fertility and sexual recovery are related but non-equivalent treatment goals.

European Journal of Endocrinology
Jan Evangelista Purkyně University in Ústí nad Labem (CZ), Krajská Zdravotní (CZ)
Good health and well-being
Pituitary Gland Disorders and Treatments
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon